Beyond Diabetes control And weight management, GLP-1 can have yet another advantage. It’s helping with migraines.
In a small study, GLP-1 drugs reduced the number of days spent with migraine in a given month.
The results, presented at the European Neurological Society Conference in Herinsky, Finland on June 21, suggest popular obesity and promising future use. Diabetic medication.
Who should take weight loss medication? Doctors share the best candidates
Approximately 40 million Americans Dealing with migrainesaccording to the World Health Organization (WHO), and for many, they are more than just a headache.
Migraines are the second reading of disorders around the world, and the above institutions say that symptoms such as severe headaches, nausea and sensitivity to light often disrupt daily activities.
Previous studies have shown that GLP-1 can reduce pressure within the skull. This has been shown to be a possible cause of migraine, according to multiple health organizations.
He led a neurologist and research, and with colleagues Simone Braca from the University of Federico II of the University of Naples in Italy, he investigated whether liraglutide, an early version of the glucagon-like peptide-1 receptor agonist (GLP-1 RA), could help patients with the milid payment.
Thirty-one adults and 26 women received daily injections of liraglutide for 12 weeks. All participants met the criteria For obesityI also continue to take my current migraine medication.
At the start of the experiment, participants reported headaches for approximately 20 days of one month. After 12 weeks of liraglutide, the average number fell about 11 days.
“Most patients reported feeling good within the first two weeks and a significant improvement in quality of life,” Braca said in a press release for the study published last month in the Journal Headache.
Migraine relief continued throughout the entire three-month observation period, researchers noted. Weight loss It was “conservative and not statistically significant.”
Participants’ weights remained roughly the same during the trial, suggesting that a reduction in headache was not linked to weight loss.
Weight loss drugs can also be useful for common medical issues, research finds
“Liraglutide is the ‘middle-aged’ GLP-1, with Ozempic and Munjaro being the new GLP-1.” Weight Loss Specialist In New York City, he spoke to Fox News Digital.
Decotiis, who was not involved in the study, said liraglutide is not as effective as weight loss or new cousins in diabetes and is not frequently used for these purposes.
“Many pharmacies don’t even stock it because of reduced demand, but it gets In the brain It’s enough to reduce migraines,” she pointed out.
The trial did not include a comparison group, and all participants and researchers knew that everyone received liraglutide, the researchers noted.
Mild Gastrointestinal side effects (mainly nausea and constipation) occurred in 38% of participants, but did not lead to treatment discontinuation.
Further studies may include other groups, such as control groups and non-obesity groups, to compare the effectiveness of the drug.
“This study was very small,” Decotiis confirmed to Fox News Digital.
Given its size and short period, the findings may be limited to Further research Experts say it is being implemented.
Click here to sign up for our health newsletter
The researchers also tested only one drug, liraglutide. This is not frequently used in the general population, like semaglutide and tilzepatide,” added Decotiis.
Visit us for more health articles www.foxnews.com/health
The team is then planning a randomized, double-blind trial that also measures pressure within the skull.
“We want to determine whether other GLP-1 drugs can provide the same relief, possibly with even fewer side effects on the gastrointestinal region,” he said in the same press release.
